Health
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., October 18, 2025--ENHERTU Followed by THP Before Surgery Resulted in Pathologic Complete Response in 67% of Patients w/High-Risk HER2 Positive Early-Stage Breast Cancer
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/63545e4f9abacc4c4b53cf0c406f361e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nWVvSlSuAXJFILfovcx9oQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/63545e4f9abacc4c4b53cf0c406f361e","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Highest reported pathologic complete response rate seen in a phase 3 registrational trial for HER2 positive early breast cancer with favorable safety profile versus standard treatment","length":183,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"DESTINY-Breast11 presented in ESMO Presidential Symposium I alongside DESTINY-Breast05 reinforces potential for Daiichi Sankyo and AstraZeneca’s ENHERTU to become a foundational treatment in curative-intent early breast cancer setting","length":234,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":417,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., October 18, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate when compared with dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in patients with high-risk, locally advanced HER2 positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. Results were presented today (291O) alongside the results from the DESTINY-Breast05 (LBA1) phase 3 trial during Presidential Symposium I at the 2025 European Society for Medical Oncology (#ESMO25) Congress.","length":921,"tagName":"p"},{"type":"text","content":"ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NASDAQ:...